Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88


p53 contributes to T cell homeostasis through the induction of pro-apoptotic SAP.

Madapura HS, Salamon D, Wiman KG, Lain S, Klein G, Klein E, Nagy N.

Cell Cycle. 2012 Dec 15;11(24):4563-9. doi: 10.4161/cc.22810. Epub 2012 Nov 19.


Wild-type p53 activates SAP expression in lymphoid cells.

Nagy N, Takahara M, Nishikawa J, Bourdon JC, Kis LL, Klein G, Klein E.

Oncogene. 2004 Nov 11;23(53):8563-70.


Restimulation-induced apoptosis of T cells is impaired in patients with X-linked lymphoproliferative disease caused by SAP deficiency.

Snow AL, Marsh RA, Krummey SM, Roehrs P, Young LR, Zhang K, van Hoff J, Dhar D, Nichols KE, Filipovich AH, Su HC, Bleesing JJ, Lenardo MJ.

J Clin Invest. 2009 Oct;119(10):2976-89. doi: 10.1172/JCI39518. Epub 2009 Sep 14.


Mdm2 inhibition induces apoptosis in p53 deficient human colon cancer cells by activating p73- and E2F1-mediated expression of PUMA and Siva-1.

Ray RM, Bhattacharya S, Johnson LR.

Apoptosis. 2011 Jan;16(1):35-44. doi: 10.1007/s10495-010-0538-0.


E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines.

Kitagawa M, Aonuma M, Lee SH, Fukutake S, McCormick F.

Oncogene. 2008 Sep 11;27(40):5303-14. doi: 10.1038/onc.2008.164. Epub 2008 Jun 2.


MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity.

Saha MN, Jiang H, Jayakar J, Reece D, Branch DR, Chang H.

Cancer Biol Ther. 2010 Jun 1;9(11):936-44. Epub 2010 Jun 27.


Induction of p53 expression and apoptosis by a recombinant dual-target MDM2/MDMX inhibitory protein in wild-type p53 breast cancer cells.

Geng QQ, Dong DF, Chen NZ, Wu YY, Li EX, Wang J, Wang SM.

Int J Oncol. 2013 Dec;43(6):1935-42. doi: 10.3892/ijo.2013.2138. Epub 2013 Oct 14.


Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21).

Drakos E, Singh RR, Rassidakis GZ, Schlette E, Li J, Claret FX, Ford RJ Jr, Vega F, Medeiros LJ.

Leukemia. 2011 May;25(5):856-67. doi: 10.1038/leu.2011.28. Epub 2011 Mar 11.


Activation of p53 by Nutlin-3a, an antagonist of MDM2, induces apoptosis and cellular senescence in adult T-cell leukemia cells.

Hasegawa H, Yamada Y, Iha H, Tsukasaki K, Nagai K, Atogami S, Sugahara K, Tsuruda K, Ishizaki A, Kamihira S.

Leukemia. 2009 Nov;23(11):2090-101. doi: 10.1038/leu.2009.171. Epub 2009 Aug 27.


Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation.

Xia M, Knezevic D, Tovar C, Huang B, Heimbrook DC, Vassilev LT.

Cell Cycle. 2008 Jun 1;7(11):1604-12. Epub 2008 Mar 17.


Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.

Ambrosini G, Sambol EB, Carvajal D, Vassilev LT, Singer S, Schwartz GK.

Oncogene. 2007 May 24;26(24):3473-81. Epub 2006 Dec 4.


Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma.

Drakos E, Thomaides A, Medeiros LJ, Li J, Leventaki V, Konopleva M, Andreeff M, Rassidakis GZ.

Clin Cancer Res. 2007 Jun 1;13(11):3380-7.


Nutlin-3 downregulates the expression of the oncogene TCL1 in primary B chronic lymphocytic leukemic cells.

Voltan R, di Iasio MG, Bosco R, Valeri N, Pekarski Y, Tiribelli M, Secchiero P, Zauli G.

Clin Cancer Res. 2011 Sep 1;17(17):5649-55. doi: 10.1158/1078-0432.CCR-11-1064. Epub 2011 Jul 13.


Blocking ETV6/RUNX1-induced MDM2 overexpression by Nutlin-3 reactivates p53 signaling in childhood leukemia.

Kaindl U, Morak M, Portsmouth C, Mecklenbräuker A, Kauer M, Zeginigg M, Attarbaschi A, Haas OA, Panzer-Grümayer R.

Leukemia. 2014 Mar;28(3):600-8. doi: 10.1038/leu.2013.345. Epub 2013 Nov 18.


HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function.

Lau LM, Nugent JK, Zhao X, Irwin MS.

Oncogene. 2008 Feb 7;27(7):997-1003. Epub 2007 Aug 13.


MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2.

Gu L, Zhu N, Findley HW, Zhou M.

Leukemia. 2008 Apr;22(4):730-9. doi: 10.1038/leu.2008.11. Epub 2008 Feb 14.


The transcription-independent mitochondrial p53 program is a major contributor to nutlin-induced apoptosis in tumor cells.

Vaseva AV, Marchenko ND, Moll UM.

Cell Cycle. 2009 Jun 1;8(11):1711-9. Epub 2009 Jun 30.


Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas.

Künkele A, De Preter K, Heukamp L, Thor T, Pajtler KW, Hartmann W, Mittelbronn M, Grotzer MA, Deubzer HE, Speleman F, Schramm A, Eggert A, Schulte JH.

Neuro Oncol. 2012 Jul;14(7):859-69. doi: 10.1093/neuonc/nos115. Epub 2012 May 16.


Simultaneous activation of p53 and inhibition of XIAP enhance the activation of apoptosis signaling pathways in AML.

Carter BZ, Mak DH, Schober WD, Koller E, Pinilla C, Vassilev LT, Reed JC, Andreeff M.

Blood. 2010 Jan 14;115(2):306-14. doi: 10.1182/blood-2009-03-212563. Epub 2009 Nov 6.


Supplemental Content

Support Center